IPO purchase proposal:

The company's OEM business manufactures a variety of medical devices for OEM customers (mainly respiratory products, contrast medium pressure syringe disposable products and orthopedic support rehabilitation equipment); and the company's OBM business develops, manufactures and sells respiratory equipment, disposable products and orthopedic support rehabilitation equipment under its own brand "Yingshi Medical". In 2015, 87.3% of the company's turnover came from the OEM business and 12.7% from the OBM business. (I) Respiratory products, (ii) Imaging CMPI disposable products, (iii) Orthopaedic support Rehabilitation Appliances, and (iv) other products accounted for 39.1%, 34.7%, 16.5% and 9.7% of 2015 turnover, respectively.

The company's total revenue increased from approximately HK $333.9 in fiscal year 2013 to approximately HK $365.2 in fiscal year 2014 and to approximately HK $429.5 in fiscal year 2015, representing a compound annual growth rate of approximately 13.4%. The company's total revenue increased by approximately 31.5% from approximately HK $84.3 million for the three months ended September 30, 2014 to approximately HK $110.8 for the three months ended September 30, 2015. Net profit in 2015 was HK $58.15 million.

The guidance price per share is between HK $1. 0 and HK $1. 25, which is about 14 times that of PE11. The valuation of the company is reasonable, so it is recommended to subscribe cautiously.